Affiliations 

  • 1 Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains, Malaysia / King Abdulaziz Hospital, National Guard Health Authority, Alahsa, Saudi Arabia
  • 2 Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains, Malaysia
  • 3 King Abdulaziz Hospital, National Guard Health Authority, Alahsa, Saudi Arabia
Pak J Pharm Sci, 2019 May;32(3 (Supplementary)):1225-1233.
PMID: 31303595

Abstract

The aim of the study is to assess and compare the impact of antiviral drug alone and in combination with antibiotic for prevention of Influenza-A H1N1 induced acute kidney injury (AKI) in hospitalized patients. Hospitalized admitted patients with confirmed diagnosis of Influenza-A H1N1 infection were divided into two groups: group 1, which received antiviral (oseltamivir) drug alone and group 2, which received antiviral (oseltamivir) in combination with empirically prescribed antibiotic. Patients of both groups were assessed for incidences of AKI by two criteria i.e Acute Kidney Injury Network (AKIN) and RIFLE. A total of 329 patients (176 for group 1 and 153 for group 2) were enrolled. According to RIFLE criteria, 23(13%) of group 1 and 9(6%) patients of groups 2 were suffered from AKI with statistically significant difference (P<0.05). Also as per AKIN criteria, the incidence of AKI is statistically significantly difference (P<0.05) between both groups with 18(10%) patients and 6(4%) patients of group 1 and 2 respectively. Length of hospitalization was statistically less (P<0.05) in group 2 patients. The incidences of AKI in Influenza-A H1N1 treated with antiviral and antibiotic combination was statistically less as compared to patients who were given antiviral alone for treatment of influenza infection.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.